Institut Català de la Salut
[Villarreal-Salazar M, Pinós T] Unitat de Patologia Neuromuscular i Mitocondrial, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. [Brull A] Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. [Nogales-Gadea G] Grup de Recerca en Malalties Neuromusculars i Neuropediàtriques, Department of Neurosciences, Institut d’Investigacio en Ciencies de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, Barcelona, Spain. [Andreu AL] EATRIS, European Infrastructure for Translational Medicine, Amsterdam, The Netherlands. [Martín MA, Arenas J] Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. Mitochondrial and Neuromuscular Diseases Laboratory, 12 de Octubre Hospital Research Institute (i+12), Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-01-18T11:34:50Z
2023-01-18T11:34:50Z
2022-12-28
McArdle disease; Glycogen phosphorylase; Research models
Enfermedad de McArdle; Glucógeno fosforilasa; Modelos de investigación
Malaltia de McArdle; Glicogen fosforilasa; Models de recerca
McArdle disease is an autosomal recessive disorder of muscle glycogen metabolism caused by pathogenic mutations in the PYGM gene, which encodes the skeletal muscle-specific isoform of glycogen phosphorylase. Clinical symptoms are mainly characterized by transient acute “crises” of early fatigue, myalgia and contractures, which can be accompanied by rhabdomyolysis. Owing to the difficulty of performing mechanistic studies in patients that often rely on invasive techniques, preclinical models have been used for decades, thereby contributing to gain insight into the pathophysiology and pathobiology of human diseases. In the present work, we describe the existing in vitro and in vivo preclinical models for McArdle disease and review the insights these models have provided. In addition, despite presenting some differences with the typical patient’s phenotype, these models allow for a deep study of the different features of the disease while representing a necessary preclinical step to assess the efficacy and safety of possible treatments before they are tested in patients.
The present manuscript was funded by grants received from the Fondo de Investigaciones Sanitarias (FIS, grant PI19/01313 and PI17/2052) and co-funded by “Fondos FEDER”.
Article
Published version
English
Metabolisme, Errors congènits del - Tractament; Múscul estriat - Patogènesi; DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Carbohydrate Metabolism, Inborn Errors::Glycogen Storage Disease::Glycogen Storage Disease Type V; Other subheadings::Other subheadings::/therapy; ANATOMY::Musculoskeletal System::Muscles::Muscle, Skeletal; ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::alteraciones congénitas del metabolismo::trastornos congénitos del metabolismo de los carbohidratos::enfermedad por almacenamiento de glucógeno::enfermedad por almacenamiento de glucógeno tipo V; Otros calificadores::Otros calificadores::/terapia; ANATOMÍA::sistema musculoesquelético::músculos::músculo esquelético
MDPI
Genes;13(1)
https://doi.org/10.3390/genes13010074
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]